Dosing & Uses
Dosage Forms & Strengths
oral spray
- 0.125 mg/mL (0.125 mg/spray)
Excessive Gastric Secretion
1-2 oral sprays (0.125-0.25 mg) q4hr PRN, not to exceed 12 sprays/day
Other Indications & Uses
Peptic ulcer disease, abdominal cramps, spastic bladder, cystitis, pylorospasm, IBS, biliary and renal colic, urinary incontinence, Parkinsonism, acute rhinitis, sialorrhea, hyperhidrosis, cholinergic poisoning
Heat prostration may be caused due to suppression of sweating
Dosage Forms & Strengths
oral spray
- 0.125 mg/mL (0.125 mg/spray)
Excessive Gastric Secretion
<12 years: Safety and efficacy not established
12 years or older: 1-2 oral sprays (0.125-0.25 mg) q4hr PRN, not to exceed 12 sprays/day
Avoid; high incidence of anticholinergic effects; avoid except in short-term situations to decrease secretions (Beers Criteria)
Excessive gastric secretion: 1-2 oral sprays (0.125-0.25 mg) q4hr PRN, not to exceed 12 sprays/day
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (0)
Serious - Use Alternative (7)
- glucagon
glucagon increases toxicity of hyoscyamine spray by Other (see comment). Avoid or Use Alternate Drug. Comment: Coadministration of anticholinergic drugs and glucagon increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. .
- glucagon intranasal
glucagon intranasal increases toxicity of hyoscyamine spray by Other (see comment). Avoid or Use Alternate Drug. Comment: Coadministration of anticholinergic drugs and glucagon increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. .
- glycopyrronium tosylate topical
glycopyrronium tosylate topical, hyoscyamine spray. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration of glycopyrronium tosylate topical with other anticholinergic medications may result in additive anticholinergic adverse effects.
- pramlintide
pramlintide, hyoscyamine spray. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility.
- revefenacin
revefenacin and hyoscyamine spray both decrease cholinergic effects/transmission. Avoid or Use Alternate Drug. Coadministration may cause additive anticholinergic effects.
- secretin
hyoscyamine spray decreases effects of secretin by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Concomitant use of anticholinergic drugs may cause a hyporesponse to stimulation testing with secretin. Discontinue anticholinergic drugs at least 5 half-lives before administering secretin.
- umeclidinium bromide/vilanterol inhaled
hyoscyamine spray, umeclidinium bromide/vilanterol inhaled. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Concomitant use with other anticholinergic-containing drugs may lead to additive anticholinergic adverse effects.
Monitor Closely (97)
- abobotulinumtoxinA
abobotulinumtoxinA increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects. .
- aclidinium
hyoscyamine spray and aclidinium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- amantadine
hyoscyamine spray, amantadine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Enhanced CNS side effects.
- amitriptyline
hyoscyamine spray and amitriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.
- amoxapine
hyoscyamine spray and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- anticholinergic/sedative combos
anticholinergic/sedative combos and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- aripiprazole
aripiprazole increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor. - atracurium
atracurium and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- atropine
atropine and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- belladonna alkaloids
belladonna alkaloids and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- belladonna and opium
hyoscyamine spray and belladonna and opium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- benperidol
benperidol increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of benperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of benperidol by pharmacodynamic antagonism. Use Caution/Monitor. - benztropine
benztropine and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- bethanechol
bethanechol increases and hyoscyamine spray decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- buprenorphine, long-acting injection
buprenorphine, long-acting injection increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of buprenorphine with anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.
- carbachol
carbachol increases and hyoscyamine spray decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- cevimeline
cevimeline increases and hyoscyamine spray decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- chlorpromazine
chlorpromazine increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of chlorpromazine by pharmacodynamic antagonism. Use Caution/Monitor. - cisatracurium
cisatracurium and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- clomipramine
hyoscyamine spray and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- clozapine
clozapine increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of clozapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of clozapine by pharmacodynamic antagonism. Use Caution/Monitor. - cyclizine
cyclizine and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- cyclobenzaprine
cyclobenzaprine and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- darifenacin
darifenacin and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- desipramine
hyoscyamine spray and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- dicyclomine
dicyclomine and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- diphenhydramine
diphenhydramine and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- donepezil
donepezil increases and hyoscyamine spray decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- donepezil transdermal
donepezil transdermal, hyoscyamine spray. Either decreases effects of the other by pharmacodynamic antagonism. Use Caution/Monitor.
- dosulepin
hyoscyamine spray and dosulepin both decrease cholinergic effects/transmission. Use Caution/Monitor.
- doxepin
hyoscyamine spray and doxepin both decrease cholinergic effects/transmission. Use Caution/Monitor.
- droperidol
droperidol increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor. - echothiophate iodide
echothiophate iodide increases and hyoscyamine spray decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- fesoterodine
fesoterodine and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- flavoxate
flavoxate and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- fluphenazine
fluphenazine increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of fluphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of fluphenazine by pharmacodynamic antagonism. Use Caution/Monitor. - galantamine
galantamine increases and hyoscyamine spray decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- glycopyrrolate
glycopyrrolate and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- glycopyrrolate inhaled
glycopyrrolate inhaled and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- haloperidol
haloperidol increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of haloperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of haloperidol by pharmacodynamic antagonism. Use Caution/Monitor. - henbane
henbane and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- homatropine
homatropine and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- huperzine A
huperzine A increases and hyoscyamine spray decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- iloperidone
iloperidone increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of iloperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of iloperidone by pharmacodynamic antagonism. Use Caution/Monitor. - imipramine
hyoscyamine spray and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- ipratropium
hyoscyamine spray and ipratropium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- levodopa
hyoscyamine spray, levodopa. Other (see comment). Use Caution/Monitor. Comment: Anticholinergic agents may enhance the therapeutic effects of levodopa; however, anticholinergic agents can exacerbate tardive dyskinesia. In high dosage, anticholinergics may decrease the effects of levodopa by delaying its GI absorption. .
- lofepramine
hyoscyamine spray and lofepramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- loxapine
loxapine increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of loxapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of loxapine by pharmacodynamic antagonism. Use Caution/Monitor. - loxapine inhaled
loxapine inhaled increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of loxapine inhaled by pharmacodynamic antagonism. Use Caution/Monitor. - maprotiline
hyoscyamine spray and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.
- meclizine
hyoscyamine spray and meclizine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- methscopolamine
hyoscyamine spray and methscopolamine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- metoclopramide intranasal
hyoscyamine spray will decrease the level or effect of metoclopramide intranasal by Other (see comment). Use Caution/Monitor. Coadministration of metoclopramide intranasal with drugs that impair GI motility may decrease systemic absorption of metoclopramide. Monitor for reduced therapeutic effect.
- neostigmine
neostigmine increases and hyoscyamine spray decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- nortriptyline
hyoscyamine spray and nortriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.
- olanzapine
olanzapine increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of olanzapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of olanzapine by pharmacodynamic antagonism. Use Caution/Monitor. - oliceridine
hyoscyamine spray increases toxicity of oliceridine by Other (see comment). Use Caution/Monitor. Comment: Anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. Monitor for signs of urinary retention or reduced gastric motility if oliceridine is coadministered with anticholinergics.
- onabotulinumtoxinA
onabotulinumtoxinA and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- orphenadrine
hyoscyamine spray and orphenadrine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- oxybutynin
hyoscyamine spray and oxybutynin both decrease cholinergic effects/transmission. Use Caution/Monitor.
- oxybutynin topical
hyoscyamine spray and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.
- oxybutynin transdermal
hyoscyamine spray and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.
- paliperidone
paliperidone increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of paliperidone by pharmacodynamic antagonism. Use Caution/Monitor. - pancuronium
hyoscyamine spray and pancuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- perphenazine
perphenazine increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of perphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of perphenazine by pharmacodynamic antagonism. Use Caution/Monitor. - physostigmine
physostigmine increases and hyoscyamine spray decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- pilocarpine
pilocarpine increases and hyoscyamine spray decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- pimozide
pimozide increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of pimozide by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of pimozide by pharmacodynamic antagonism. Use Caution/Monitor. - prabotulinumtoxinA
hyoscyamine spray, prabotulinumtoxinA. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects.
- pralidoxime
hyoscyamine spray and pralidoxime both decrease cholinergic effects/transmission. Use Caution/Monitor.
- prochlorperazine
prochlorperazine increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. - promethazine
promethazine increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
- propantheline
hyoscyamine spray and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.
- protriptyline
hyoscyamine spray and protriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.
- pyridostigmine
pyridostigmine increases and hyoscyamine spray decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- quetiapine
quetiapine increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of quetiapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of quetiapine by pharmacodynamic antagonism. Use Caution/Monitor. - rapacuronium
hyoscyamine spray and rapacuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- rimantadine
hyoscyamine spray, rimantadine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Enhanced CNS side effects.
- risperidone
risperidone increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of risperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of risperidone by pharmacodynamic antagonism. Use Caution/Monitor. - rivastigmine
rivastigmine increases and hyoscyamine spray decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- rocuronium
hyoscyamine spray and rocuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- scopolamine
hyoscyamine spray and scopolamine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- solifenacin
hyoscyamine spray and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.
- succinylcholine
succinylcholine increases and hyoscyamine spray decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- thioridazine
thioridazine increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of thioridazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of thioridazine by pharmacodynamic antagonism. Use Caution/Monitor. - thiothixene
thiothixene increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of thiothixene by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of thiothixene by pharmacodynamic antagonism. Use Caution/Monitor. - tiotropium
hyoscyamine spray and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- tolterodine
hyoscyamine spray and tolterodine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- trazodone
hyoscyamine spray and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
- trifluoperazine
trifluoperazine increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor. - trihexyphenidyl
hyoscyamine spray and trihexyphenidyl both decrease cholinergic effects/transmission. Use Caution/Monitor.
- trimipramine
hyoscyamine spray and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- trospium chloride
hyoscyamine spray and trospium chloride both decrease cholinergic effects/transmission. Use Caution/Monitor.
- umeclidinium bromide
umeclidinium bromide and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor. If possible, avoid coadministration of additional anticholinergic agents
- vecuronium
hyoscyamine spray and vecuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- ziprasidone
ziprasidone increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of ziprasidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of ziprasidone by pharmacodynamic antagonism. Use Caution/Monitor.
Minor (4)
- dimenhydrinate
dimenhydrinate increases toxicity of hyoscyamine spray by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- donepezil
donepezil decreases effects of hyoscyamine spray by pharmacodynamic antagonism. Minor/Significance Unknown.
- galantamine
galantamine decreases effects of hyoscyamine spray by pharmacodynamic antagonism. Minor/Significance Unknown.
- rimantadine
rimantadine increases effects of hyoscyamine spray by pharmacodynamic synergism. Minor/Significance Unknown.
Adverse Effects
Frequency Not Defined
Headache
Nervousness
Blurred vision
Cycloplegia/mydriasis
Increased IOP
Tachycardia
Urinary retention
Xerostomia
Warnings
Contraindications
Glaucoma, obstructive uropathy, GI obstruction, myasthenia gravis, toxic megacolon, unstable cardiovascular status in acute hemorrhage, severe ulcerative colitis
Cautions
Autonomic neuropathy, hiatal hernia, reflux esophagitis, renal dz, hyperthyroidism, tachyarrhythmia, CHF, salivary secretion disorder, BPH
Pregnancy & Lactation
Pregnancy Category: C
Lactation: excreted in breast milk, use caution (may suppress lactation)
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Parasympatholytic, atropine-like effects, especially peripherally, blocks the action of ACh at parasympathetic sites in smooth muscle, secretory glands, and CNS
Pharmacokinetics
Absorption: rapid & complete
Half-Life: 2-3.5 hr
Protein Bound: 50%
Metabolism: Partially hydrolyzed to tropic acid & tropine
Excretion: Urine
Vd
- Adults: 1.2-1.9 L/kg
- Children 3.5-16 yo: 1.1-3.7 L/kg
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| hyoscyamine sulfate oral - | 0.125 mg tablet |  | |
| hyoscyamine sulfate oral - | 0.125 mg tablet |  | |
| hyoscyamine sulfate oral - | 0.125 mg tablet |  | |
| hyoscyamine sulfate oral - | 0.125 mg/5 mL elixir |  | |
| hyoscyamine sulfate oral - | 0.125 mg tablet |  | |
| hyoscyamine sulfate oral - | 0.125 mg tablet |  | |
| hyoscyamine sulfate oral - | 0.125 mg tablet | | |
| hyoscyamine sulfate oral - | 0.125 mg tablet |  | |
| hyoscyamine sulfate oral - | 0.125 mg tablet |  | |
| hyoscyamine sulfate oral - | 0.375 mg tablet |  | |
| hyoscyamine sulfate oral - | 0.125 mg tablet |  | |
| hyoscyamine sulfate oral - | 0.375 mg tablet |  | |
| hyoscyamine sulfate oral - | 0.125 mg/mL drops |  | |
| Symax-SR oral - | 0.375 mg tablet |  | |
| Symax-SL sublingual - | 0.125 mg tablet |  | |
| Levbid oral - | 0.375 mg tablet | | |
| Hyosyne oral - | 0.125 mg/mL drops |  | |
| Hyosyne oral - | 0.125 mg/5 mL elixir |  | |
| Ed-Spaz oral - | 0.125 mg tablet |  | |
| Symax Fastabs oral - | 0.125 mg tablet |  | |
| hyoscyamine sulfate sublingual - | 0.125 mg tablet |  | |
| hyoscyamine sulfate sublingual - | 0.125 mg tablet |  | |
| hyoscyamine sulfate sublingual - | 0.125 mg tablet |  | |
| hyoscyamine sulfate sublingual - | 0.125 mg tablet |  | |
| hyoscyamine sulfate sublingual - | 0.125 mg tablet |  | |
| hyoscyamine sulfate sublingual - | 0.125 mg tablet |  | |
| NuLev oral - | 0.125 mg tablet |  | |
| Levsin/SL sublingual - | 0.125 mg tablet | | |
| Oscimin oral - | 0.125 mg tablet |  | |
| Anaspaz oral - | 0.125 mg tablet |  | |
| Symax Duotab oral - | 0.125 mg-0.25 mg (0.375 mg) tablet |  | |
| Levsin oral - | 0.125 mg tablet | |
Copyright © 2010 First DataBank, Inc.
Patient Handout
hyoscyamine sulfate oral
HYOSCYAMINE - ORAL
(hi-oh-SYE-uh-meen)
COMMON BRAND NAME(S): Anaspaz, Cystospaz, Donnamar, Levsin
USES: Hyoscyamine is used to treat a variety of stomach/intestinal problems such as cramps and irritable bowel syndrome. It is also used to treat other conditions such as bladder and bowel control problems, cramping pain caused by kidney stones and gallstones, and Parkinson's disease. In addition, it is used to decrease side effects of certain medications (drugs used to treat myasthenia gravis) and insecticides.This medication works by decreasing acid production in the stomach, slowing down the natural movements of the gut, and relaxing muscles in many organs (such as the stomach, intestines, bladder, kidney, gallbladder). Hyoscyamine also lessens the amount of certain body fluids (such as saliva, sweat). This medication belongs to a class of drugs known as anticholinergics/antispasmodics.
HOW TO USE: Take this medication by mouth as prescribed, usually 30-60 minutes before meals, or as directed by your doctor.Dosage is based on your medical condition and response to therapy. Do not increase your dose or take it more often than prescribed without consulting your doctor. Adults and children 12 years and older should not take more than 1.5 milligrams in 24 hours. Children aged 2 to 12 years should not take more than 0.75 milligrams in 24 hours. Ask your doctor or pharmacist for more information.Antacids lower the absorption of hyoscyamine. If you use antacids, take them after meals and take hyoscyamine before meals; or take antacids at least 1 hour after taking hyoscyamine.Drink plenty of fluids while taking this medication unless your doctor directs you otherwise.Tell your doctor if your condition lasts or gets worse.
SIDE EFFECTS: Dizziness, drowsiness, blurred vision, dry mouth, vision problems, headache, trouble sleeping, constipation, flushing, dry skin, and decreased sweating may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.To relieve dry mouth, suck on (sugarless) hard candy or ice chips, chew (sugarless) gum, drink water or use a saliva substitute.Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.Tell your doctor right away if you have any serious side effects, including: mental/mood changes (such as confusion, unusual excitement), fast/irregular heartbeat, difficulty urinating, decreased sexual ability, loss of coordination, trouble speaking, vomiting.Get medical help right away if you have any very serious side effects, including: eye pain/swelling/redness, vision changes (such as seeing rainbows around lights at night).A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: Before taking hyoscyamine, tell your doctor or pharmacist if you are allergic to it; or to atropine; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history, especially of: enlarged prostate, urinary blockage problems, certain stomach/intestinal problems (such as slow gut, blockage, severe ulcerative colitis, infection), personal or family history of glaucoma (angle-closure type), overactive thyroid, heart problems (such as coronary heart disease, heart failure, fast heartbeat, arrhythmias), high blood pressure, kidney disease, heartburn problems (acid reflux, hiatal hernia), certain nervous system problem (autonomic neuropathy), myasthenia gravis.Contact lens wearers may need to use wetting eye drops since this medication can cause dry eyes.This drug may make you dizzy or drowsy or blur your vision. Alcohol or marijuana (cannabis) can make you more dizzy or drowsy. Do not drive, use machinery, or do anything that needs alertness or clear vision until you can do it safely. Limit alcoholic beverages. Talk to your doctor if you are using marijuana (cannabis).This drug may increase the risk for heatstroke because it decreases sweating. Avoid becoming overheated in hot weather, saunas, and during exercise or other strenuous activity.Older adults may be more sensitive to the side effects of this drug, especially confusion, drowsiness, unusual excitement, constipation, and difficulty urinating. Confusion and drowsiness can increase the risk of falling.Children may be more sensitive to the effects of this drug.During pregnancy, hyoscyamine should be used only when clearly needed. Discuss the risks and benefits with your doctor.This drug passes into breast milk. Consult your doctor before breast-feeding.
DRUG INTERACTIONS: See also How to Use section.Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.Some products that may interact with this drug are: certain anti-arrhythmic drugs (such as disopyramide, quinidine), anticholinergic drugs (such as atropine, glycopyrrolate, scopolamine), antispasmodic drugs (such as clidinium, dicyclomine, propantheline), certain anti-Parkinson's drugs (such as trihexyphenidyl), certain azole anti-fungal drugs (ketoconazole, itraconazole), belladonna alkaloids, bisphosphonate drugs (such as alendronate, risedronate), corticosteroids (such as prednisone), digoxin (slow-dissolving tablets), MAO inhibitors (isocarboxazid, linezolid, metaxalone, methylene blue, moclobemide, phenelzine, procarbazine, rasagiline, safinamide, selegiline, tranylcypromine), potassium tablets/capsules, pramlintide.Tell your doctor or pharmacist if you are taking other products that cause drowsiness such as opioid pain or cough relievers (such as codeine, hydrocodone), alcohol, marijuana (cannabis), drugs for sleep or anxiety (such as alprazolam, lorazepam, zolpidem), muscle relaxants (such as carisoprodol, cyclobenzaprine), or antihistamines (such as cetirizine, diphenhydramine).Check the labels on all your medicines (such as allergy or cough-and-cold products) because they may contain ingredients that cause drowsiness. Ask your pharmacist about using those products safely.This product can affect the results of certain lab tests. Make sure laboratory personnel and your doctors know you use this drug.
OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center. Symptoms of overdose may include hot/dry skin, fever, unusual excitement, fast/irregular heartbeat, seizures.
NOTES: Do not share this medication with others.Management of digestive disorders may include lifestyle changes such as stress reduction programs, exercise, stopping smoking, and dietary changes to increase the effectiveness of this medicine. Talk to your doctor or pharmacist about lifestyle changes that might benefit you.
MISSED DOSE: If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up.
STORAGE: Store at room temperature away from light and moisture. Do not store in the bathroom. Keep all medications away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.
Information last revised April 2022. Copyright(c) 2022 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
